达托霉素治疗血液病合并皮肤软组织感染的临床观察

Clinical observation on daptomycin for the treatment of hematopathy combined with skin and soft tissue infection

摘要:

目的 评价达托霉素治疗血液病合并皮肤软组织感染的疗效和安全性。方法 回顾性分析2018年3月—2019年3月某院使用达托霉素治疗的血液病合并皮肤软组织感染患者的临床资料、实验室检查结果以及达托霉素治疗的效果和安全性，按患者是否存在粒细胞缺乏分为粒细胞缺乏组与非粒细胞缺乏组，比较两组治愈率的差异。结果 共18例血液病合并皮肤软组织感染的患者使用达托霉素治疗，14例患者达到临床治愈，治愈率为77.8%；粒细胞缺乏组与非粒细胞缺乏组患者治愈率比较（75.0% VS 80.0%），差异无统计学意义（P>0.05）。患者体温下降1℃中位时间12（4~24）h，退热中位时间1.65（0.2~4）d，未出现与达托霉素相关的不良反应。结论 达托霉素治疗血液病合并皮肤软组织感染安全有效，不良反应少。

Abstract:

Objective To evaluate the efficacy and safety of daptomycin in the treatment of hematopathy associated with skin and soft tissue infection(SSTI). Methods Clinical data, laboratory test results as well as efficacy and safety of daptomycin in the treatment of hematopathy associated with SSTI in patients in a hospital from March 2018 to March 2019 were analyzed retrospectively, according to whether there was agranulocytosis or not, patients were divided into agranulocytosis group and non-agranulocytosis group, difference in cure rate between two groups was compared. Results A total of 18 patients with hematopathy complicated with SSTI were treated with daptomycin, 14 of whom (77.8%) were clinically cured; there was no significant difference in the cure rate between agranulocytosis group and non-agranulocytosis group (75.0% vs 80.0%, P>0.05). The median time of patients' temperature dropped by 1℃ was 12 (4-24) hours, and the median time of abatement of fever was 1.65 (0.2-4) days, adverse reaction related to daptomycin was not found. Conclusion Daptomycin is safe and effective in the treatment of hematopathy with SSTI, with few adverse reaction.